Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: perigen.com
Global Number of Employees (Latest): 49
Year Founded: 1995
Total Amount Raised (CAD mm)†: 14.95
Total Rounds of Funding**:5
Latest Post-Money Valuation ($ mm) 1.00
Latest Pre-Money Valuation ($ mm) 1.00
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
PeriGen, Inc. designs and develops perinatal and fetal monitoring software solutions and clinical decision support systems that allow clinicians to make real-time decisions about the mothers and babies in their care. The company offers Perinatal decision-support software, a modular system that handles burdensome number-crunching, counting, and analysis. Its solutions include PeriWatch Vigilance, an automated early warning system that notifies clinicians about patients whose conditions are worsening to provide clinical decision support; PeriWatch Surveillance, a tool designed by clinicians that serves bedside clinicians, nurse managers, and physicians for surveillance, documentation, and clinical decision support; and PeriWatch Command Center, an enterprise wide telehealth platform that allows remote perinatal telemonitoring across multiple facilities from a central monitoring location. The ompany offers clinical escalation management tool for intrapartum chain of command. PeriGen, Inc. was formerly known as E&C Medical Intelligence Inc. and changed its name to PeriGen, Inc. in April 2009. The company was founded in 1995 and is based in Cary, North Carolina with additional offices in Quebec, Canada; and Rishon LeZion, Israel. As of April 27, 2021, PeriGen, Inc. operates as a subsidiary of Halma plc.


Financial Information (Currency: CAD, in mm)
Total Revenue
 27.2
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 49
Net Debt
-
U.S. Number of Employees 2021
 49
U.S. Number of Employees 2020
 46
U.S. Last Year Employee Growth %
 6.5
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Sappern, Matthew D.
Chief Executive Officer
Coats, W. John
Chief Financial officer and Controller
Hagan, Lynne
Director of Marketing
Long, Chip
Senior Vice President of Growth & Development
Bendavid, Bruno
Senior Vice President of Product Management
Blanks, Natan
Senior Vice President and Technology Solutions Architect
Cypher, Rebecca
Chief Nursing Officer
Garite, Thomas J.
Chief Medical Officer
Hamilton, Emily F.
Senior Vice President of Clinical Research
Queffelec, Denise
Senior Vice President of Consulting Services

Key Board Members
Name
Title
Reardon, John 
Chairman
Bauer, Stacey Lynn
Director
Gomez, John P.
Director
Jahns, David W.
Director
Moragne, John Hutchins
Director
Stafford, C. Richard
Director


Primary Industry Classification
Health Care Technology


Primary Office Location
100 Regency Forest Drive Suite 200 | Cary, NC | 27518 | United States
Phone: 984 208 6888   Fax: 984 208 7876

Parent Company
Halma plc (LSE:HLMA)

Prior Investors
Ambina Partners LLC, Atalaya Capital Management LP, Denali Ventures I, Denali Ventures LLC, Galen Partners (David Jahns), HiTec Investors Group, Salmon River Capital LLC (S. Lewis), Sunstone Partners Management, LLC, Trident Capital, Inc. (John Moragne, John Reardon), Van Leer Ventures Jerusalem


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Hill-Rom Holdings, Inc., WatchChild Fetal Monitoring System
As of September 21, 2016, WatchChild Fetal Monitoring System of Hill-Rom Holdings, Inc. was acquired by PeriGen Inc. WatchChild Fetal Monitoring System of Hill-Rom Holdings, Inc. offers solution for perinatal clinical charting and surveillance.

United States and Canada
Health Care Technology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-27-2021
Apr-27-2021
Merger/Acquisition
Target
PeriGen, Inc.
Halma plc (LSE:HLMA)
Trident Capital, Inc.,Galen Partners,Ambina Partners LLC,Atalaya Capital Management LP
58.00
Sep-27-2016
Sep-27-2016
Private Placement
Target
PeriGen, Inc.
Trident Capital, Inc.,Galen Partners,Ambina Partners LLC

-
Sep-22-2016
Sep-21-2016
Merger/Acquisition
Buyer
Hill-Rom Holdings, Inc., WatchChild Fetal Monitoring System
PeriGen, Inc.
Hill-Rom Holdings, Inc.
-
Feb-22-2013
-
Private Placement
Target
PeriGen, Inc.


6.42
Jan-27-2010
Jan-27-2010
Private Placement
Target
PeriGen, Inc.
Salmon River Capital LLC

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-16-2023
Product-Related Announcements
PeriGen Inc. Introduces Clinical Escalation Management Tool for Intrapartum Chain of Command
Dec-14-2022
Client Announcements
Memora Health and Perigen Partner to Deliver Innovative Solutions in Maternal and Infant Care
Apr-12-2022
Executive/Board Changes - Other
PeriGen Inc. Announces That Kimberlee McKay, MD F.A.C.O.G. Is Joining as A Physician Consultant
Nov-10-2021
Product-Related Announcements
PeriGen Deploys Mobile Version of PeriWatch Vigilance to Further Protect Moms and Babies During Childbirth
Apr-27-2021
M&A Transaction Closings
Halma plc (LSE:HLMA) acquired PeriGen, Inc. from Ambina Partners LLC, Atalaya Capital Management LP and others for $58 million.

M&A Advisors
Canaccord Genuity LLC, Lowenstein Sandler LLP, Robert W. Baird & Co. Incorporated


Advisors
M&A Advisors
Canaccord Genuity LLC, Lowenstein Sandler LLP, Robert W. Baird & Co. Incorporated
Private Placement Advisors
Robert W. Baird & Co. Incorporated


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 07:05 PM
PeriGen, Inc.
PeriGen Inc
Reports
46
GlobalData

Jun 16, 2023 01:01 AM
PeriGen, Inc.
PeriGen Inc
Reports
46
GlobalData

Mar 14, 2023 11:01 PM
PeriGen, Inc.
PeriGen Inc
Reports
46
GlobalData

Dec 14, 2022 06:31 PM
PeriGen, Inc.
PeriGen Inc
Reports
47
GlobalData

Sep 19, 2022 06:59 AM
PeriGen, Inc.
PeriGen Inc
Reports
47
GlobalData

Jun 15, 2022 01:10 AM
PeriGen, Inc.
PeriGen Inc
Reports
47
GlobalData

Mar 13, 2022 02:36 AM
PeriGen, Inc.
PeriGen Inc
Reports
46
GlobalData

Dec 13, 2021 11:36 PM
PeriGen, Inc.
PeriGen Inc
Reports
21
GlobalData

Sep 15, 2021 12:47 AM
PeriGen, Inc.
PeriGen Inc
Reports
17
GlobalData

Jun 14, 2021 05:59 AM
PeriGen, Inc.
PeriGen Inc
Reports
18


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Artificial Intelligence-based Software Solutions, EC DataMgr, PeriCALM Plus

Key Board Members Details
Name
Title
Phone
Fax
Email
Reardon, John 
Chairman
984 208 6888
984 208 7876

Bauer, Stacey Lynn
Director
(203) 653-6473
(508) 393-1978
sbauer@galen.com
Gomez, John P.
Director
984 208 6888
984 208 7876
-
Jahns, David W.
Director
203-653-6440
212-218-4999
djahns@galen.com
Moragne, John Hutchins
Director
(650) 233-4300
(650) 233-4333
jmoragne@tridentcap.com
Stafford, C. Richard
Director
984 208 6888
984 208 7876
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Sappern, Matthew D.
Chief Executive Officer
984 208 6888
984 208 7876
-
Coats, W. John
Chief Financial officer and Controller
984 208 6888
984 208 7876
-
Hagan, Lynne
Director of Marketing
984 208 6888
984 208 7876
-
Long, Chip
Senior Vice President of Growth & Development
984 208 6888
984 208 7876
-
Bendavid, Bruno
Senior Vice President of Product Management
984 208 6888
984 208 7876
-
Blanks, Natan
Senior Vice President and Technology Solutions Architect
984 208 6888
984 208 7876
-
Cypher, Rebecca
Chief Nursing Officer
984 208 6888
984 208 7876
-
Garite, Thomas J.
Chief Medical Officer
984 208 6888
984 208 7876

Hamilton, Emily F.
Senior Vice President of Clinical Research
984 208 6888
984 208 7876
-
Queffelec, Denise
Senior Vice President of Consulting Services
984 208 6888
984 208 7876
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
